MALG vs OKT3 following renal transplantation: a randomized prospective trial.
Frey
D J
DJ
Department of Surgery, University of Minnesota Medical School, Minneapolis.
Matas
A J
AJ
Gillingham
K J
KJ
Canafax
D
D
Payne
W D
WD
Dunn
D L
DL
Sutherland
D E
DE
Najarian
J S
JS
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D003365:Costs and Cost Analysis; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D016853:Muromonab-CD3; D011446:Prospective Studies; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3